LONDON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS” or the “company”), a biotechnology company dedicated to accelerating patient access to evidence-based ...

COMPASS Pathways plc (NASDAQ:CMPS) is among the Best Get Rich Fast Stocks to Buy Right Now. As of December 24, COMPASS Pathways plc (NASDAQ:CMPS) has a ‘Buy’ or equivalent rating from the majority of ...

Compass Pathways reported operating expenses of $48.4 million, slightly above Canaccord's estimate of $48 million. Kulkarni highlighted that Compass Pathways is nearing completion of its COMP005 Phase ...

Compass Pathways, which has been navigating the challenges of the pharmaceutical industry, holds a market capitalization of $568.61 million. Despite a difficult period, the company maintains a ...

Maxim Group analyst Jason McCarthy has maintained their bullish stance on CMPS stock, giving a Buy rating today. Jason McCarthy’s Buy rating for COMPASS Pathways is influenced by several factors.

With timelines for the submission of approval for MDMA-assisted therapy becoming more clear, COMPASS Pathways CMPS has provided their own estimation on when psilocybin-assisted therapy may obtain ...

View source version on businesswire.com: https://www.businesswire.com/news/home/20251104736485/en/ ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the first ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the fourth ...

Newly created role of Chief Patient Officer reinforces Compass' vision of working to achieve broad and equitable access to COMP360, if approved Compass Pathways plc (Nasdaq: CMPS) ("Compass"), a ...

Artificial Intelligence (AI) is rapidly penetrating a number of different sectors, including healthcare. The use of AI in mental health has opened up the possibility of new avenues of care, ...

With an estimated 51.5 million U.S. adults suffering from mental illness and the psychedelic drug market projected to grow at ...